Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Shin Nippon Biomedical Laboratories Ltd. (2395:JPX), powered by AI.
Shin Nippon Biomedical Laboratories Ltd. is currently trading at ¥1,079. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Shin Nippon Biomedical Laboratories Ltd. on Alpha Lenz.
Shin Nippon Biomedical Laboratories Ltd.'s P/E ratio is 9.1.
“Shin Nippon Biomedical Laboratories Ltd. trades at a P/E of 9.1 (undervalued) with solid ROE of 13.3%. 3Y revenue CAGR of 22.2% highlights clear growth momentum.”
Ask for details →Shin Nippon Biomedical Laboratories Ltd. is a leading provider in the field of preclinical and clinical research services. The company primarily focuses on delivering comprehensive and high-quality research solutions to the pharmaceutical, biotechnology, and medical device sectors. Known for its advanced technological capabilities and scientific expertise, Shin Nippon Biomedical Laboratories plays a critical role in the drug development and medical research processes, offering services such as toxicology studies, pharmacokinetics, and bioanalysis. Its operations are pivotal in ensuring the safety and efficacy of new therapeutic compounds before they proceed to market. Based in Japan, the firm has established a robust presence in the global research landscape, underpinned by its adherence to rigorous regulatory standards and commitment to innovative research methodologies. Its contributions are vital in expediting the development of new medical treatments and enhancing the overall efficiency of the healthcare and life sciences industries.
“Shin Nippon Biomedical Laboratories Ltd. trades at a P/E of 9.1 (undervalued) with solid ROE of 13.3%. 3Y revenue CAGR of 22.2% highlights clear growth momentum.”
Ask for details →Shin Nippon Biomedical Laboratories Ltd. (ticker: 2395) is a company listed on JPX in the Healthcare sector (Diagnostics & Research). It has approximately 1,541 employees. Market cap is $44.9B.
The current price is 1,079 with a P/E ratio of 9.12x and P/B of 1.12x.
ROE is 13.29% and operating margin is 9.21%. Annual revenue is $32.4B.